Both general DNA methylation inhibitors and Wnt-pathway-targeting anticancer drugs are under development [35, 36]. Our results that linked Wnt antagonist hypermethylation

and EGFR-TKI response suggest that the treatment paradigm combining epigenetic drugs and EGFR-TKI may be a potential and attractive therapeutic option for patients with NSCLC. Authors’ informations Supported by grants from National Natural Sciences Foundation Distinguished Young Scholars (81025012), National Natural Sciences Foundation General Program (81172235), Beijing Health Systems Academic Leader (2011-2-22). Acknowledgement We thank Dr.BM Zhu for her critical review of this manuscript and Dr Ning Wang in the radiological department of Beijing Cancer Hospital for his assessments selleck kinase inhibitor of the response of treatment. We thank Dr.Guoshuang Feng in (Chaoyang District Center for Disease Control and Prevention) for statistical analysis. Electronic supplementary material Additional file 1: Figure S1. Methylated and unmethyalted bands of Wnt antagonist genes and wild/mutant EGFR. S1: LDE225 The example graphs of methylated

and unmethyalted bands of Wnt antagonist genes (A) and EGFR wild (B) and mutation types (C, D) by methylation specific PCR and DHPLC respectively. Figure S2 PFS with different epigenotypes of Wnt antagonist genes. Figure2S A-F.Kaplan-Meier curves of comparing the progression free survival of patients with

different epigenotypes of SFRP1(A), SFRP2 (B), DKK3 (C), APC (D), CDH1 (E) and combination analysis (F). Figure S3 OS with different epigenotypes of Wnt antagonist genes. Figure3S A-F. Exoribonuclease Kaplan-Meier curves of comparing the overall survival of patients with different epigenotypes of SFRP1 (A), SFRP2 (B), DKK3 (C), APC (D), CDH1 (E) and combination analysis (F). (PPT 746 KB) References 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008,58(2):71–96.PubMedCrossRef 2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al.: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539–4544.PubMedCrossRef 3. Sekido Y, Fong KM, Minna JD: Progressin understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998, 1378:F21-F59.PubMed 4. Fossella F, Pereira JR, Pawel JV, Pluzanska A, Gorbounova V, Kaukel E, et al.: Randomized, multinational, phase III study of docetaxel plus patinnum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the TAX326 Study Group. J Clin Oncol 2003,21(16):3016–3024.PubMedCrossRef 5. Ramalingarm S: First-line chemotherapy for advanced-stage non-small cell lung cancer: focus on docetaxel. Clin Lung Cancer 2005, 7:S77-S82.CrossRef 6.